Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Menopause

Volumn 20, Issue 7, 2013, Pages 721-726

  Bell, Robin J ^a   Schwarz, Max ^a   Fradkin, Pamela ^a   Robinson, Penelope J ^a   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Breast cancer; Guidelines; Oral adjuvant endocrine therapy

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG USE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORAL ADJUVANT ENDOCRINE THERAPY; QUESTIONNAIRE; SELF REPORT; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; AUSTRALIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; QUESTIONNAIRES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVORS; TAMOXIFEN;

EID: 84879990239     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31827ce094     Document Type: Article

References (23)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-3796.
2. Cancer Australia. Available at: http://guidelines.nbocc.org.au/ guidelines/guideline-2.pdf. 2008.
3. Cancer Australia. Available at: http://guidelines.nbocc.org.au/ guidelines/guideline-6.pdf. 2011.
4. Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(suppl 6):vi12-vi24.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2. 2012.
6. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518.
7. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
8. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-492.
9. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109: 832-839.
10. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-562.
11. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-4128.
12. Bell RJ, Fradkin P, Schwarz M, Davis SR. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 2012;10.1097/gme.0b013e3182610cab.
13. Lijovic M, Davis SR, Fradkin P, et al. Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer. BMC Cancer 2008;8:126.
14. Bell RJ, Lijovic M, Fradkin P, Davis SR. A pragmatic approach to the classification of menopausal status for community-based research. Menopause 2008;15:978-983.
15. Anastrozole (Arimidex) for the treatment of hormone-dependent early breast cancer in postmenopausal women. Available at: http://www.nps.org.au/- data/assets/pdf-file/0005/14684/anastrozole.pdf.
16. Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994;57:71-77.
17. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-592.
18. Schwartz GF, Reis-Fihlo J, Pusztai L, et al. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Cancer 2012;118:2031-2038.
19. Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 2012;131:491-499.
20. Yung RL, Hassett MJ, Chen K, et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst 2012.
21. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-784.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
23. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of longterm outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-444.